|
Download PDF
|
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin,
Sarcomas
Introduction
In 2008, the six tumor types covered in this report are forecast
to account for over 961,000 new cases of cancer. Collectively,
the 32 different drugs in Phase III development for the six
tumor types are forecast to achieve $4,789m in sales by 2017.
This constitutes a significant proportion of the oncology
market, thus representing ample commercial opportunities for
drug developers.
Scope
-
Examination of the solid cancer pipeline with in-depth clinical
and commercial profiles of Phase III candidates for six tumor
types
-
Seven major pharmaceutical market sales forecasts for Phase III
pipeline products through to 2017 with product-specific
assumptions
-
Segmentation and analysis of the current solid tumor pipeline
by developmental phase, drug class and indication for six tumor
types
-
Insight and analysis of market potential including commercial
opportunity, epidemiology, commonalities across cancers and
discussion of unmet needs
Highlights
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and brivanib
(BMS-582664; Bristol-Myers Squibb) show the most potential in
the colorectal cancer pipeline. Aflibercept has shown activity
following failure of prior standard Avastin (bevacizumab;
Genentech/Roche), while brivanib's novel mechanism of action
could represent a first-in-class therapy.
Melanoma is the most popular R&D target of the six tumor types
covered in this report, due to persistent high unmet needs and a
substantial incidence. Elesclomol (STA-4783; Synta
Pharmaceuticals/GlaxoSmithKline) currently shows the most
potential at present, although only if successful Phase II
results can be replicated in Phase III studies.
First-line axitinib (AG-13736; Pfizer) and Gemzar (gemcitabine;
Eli Lilly) showed similar response rates and overall survival to
first-line Gemzar and Tarceva (erlotinib; Genentech/Roche) in
pancreatic cancer. If this can be replicated in Phase III
trials, approval is likely, given that Tarceva was approved
based on a 2-week survival benefit.
Reasons to Purchase
-
Identify key drugs and companies within the oncology pipeline
based on sales forecasts to 2017 and Datamonitor drug assessment
-
Characterize unmet need and poorly served markets within
oncology and assess the potential for pipeline products to fulfil them
-
Assess the shifting oncology market dynamic and how future
treatment of solid tumors will incorporate pipeline products
View
Table Of Contents >
|
